Use of the cathelicidin LL-37 and derivatives thereof for wound healing
AssigneeLipopeptide AB
InventorsMona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
Life of this patent
Estimating the term…
Abstract
Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithalial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.
Claims19
A method of regenerating epithelial cells, healing of wound epithelium or healing of wound stroma, which comprises administering to a subject a peptide comprising an amino acid sequence containing at least 25 amino acids of the N-terminal fragment of SEQ ID NO:
- 1 or a pharmaceutically acceptable salt or ester or amide thereof, wherein said peptide enhances proliferation of epithelial and/or stromal cells through a non-lytic mechanism.
A pharmaceutical composition for topical application to epithelial cells comprising:
- a) a peptide comprising an amino acid sequence containing at least 25 amino acids of the N-terminal fragment of LL-37 (SEQ ID NO:
- 1) or a pharmaceutically acceptable salt or ester or amide thereof;
- and
- b) a bilayer forming polar lipid carrier comprising a galactolipid.
A kit for culturing of epithelial and/or stromal cells comprising:
- (a) a peptide comprising an amino acid sequence containing at least 25 amino acids of the N-terminal fragment of LL-37 (SEQ ID NO:1) or a pharmaceutically acceptable salt or ester or amide thereof;
- and
- (b) a cytotoxicity reducing agent comprising a galactolipid.
A growth medium for culturing epithelial and/or stromal cells comprising:
- (a) a peptide comprising an amino acid sequence containing at least 25 amino acids of the N-terminal fragment of LL-37 (SEQ ID NO:1), or a pharmaceutically acceptable salt or ester or amide thereof;
- (b) a cytotoxicity reducing agent comprising a galactolipid;
- and
- (c) a basal medium.
Dependencies are inferred from the claim text.